Pressmeddelande Publicerat: 2018-02-27 09:26:00

EQL Pharma AB: Paracetamol EQL Pharma approved

The drug Paracetamol EQL Pharma has now been approved for sale by the Swedish Medicines Agency. Paracetamol EQL Pharma is used for aches and pains of different types (e.g., headache, toothache, menstrual pain, muscle and joint pain and rheumatic pain) and fever (e.g. during colds).

Paracetamol is a very common drug and sells in high volumes in all markets in Europe. EQL Pharma has found their niche by choosing strengths and packaging variants that are less exposed to competition but still have an interesting market size.
This niche market has a turnover of approximately SEK 20 million annually and is home to a few competitors, in line with the EQL Pharma's long-term strategy.

The product is expected to be launched in the second half of 2018.

For further information, please contact: Christer Fåhraeus CEO EQL Pharma AB (publ) Phone: +46 (0) 705 - 60 90 00 E-mail: Website: 
About EQL Pharma  EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets eight (8) niche generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (8) people and is listed on AktieTorget. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China. 

EQL Pharma AB

EQL Pharma är specialiserat på att utveckla och sälja generika, det vill säga läkemedel som är medicinskt likvärdiga med originalläkemedel. Bolaget marknadsför för närvarande 8 nisch-generika (dvs generika med liten eller ingen konkurrens bortsett från originalläkemedlet) på den svenska och danska marknaden, i tillägg till dessa finns en betydande pipeline av ytterligare nisch-generika för lansering 2018 och framåt. Verksamheten är för närvarande helt inriktad på receptbelagda läkemedel i Norden. EQL Pharma bedriver sin verksamhet i Lund, sysselsätter 7 (8) personer och är noterat på AktieTorget. EQL Pharma bedriver ett omfattande utvecklingsarbete i samarbete med ledande kontraktstillverkare och större läkemedelsbolag i bland annat Indien och Kina.

Stortorget 1,
222 23 LUND
+46 46 12 01 70